NCT01700699Unknown不适用
Impact of BRAFV600E Intratumor Heterogeneity on the Efficacy of Tyrosine Kinase Inhibitors in the Treatment of Radioiodine-resistant Thyroid Cancer
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Percentage of BRAFV600E alleles in tumor tissue before TKI treatment
研究概览
简要总结
- Background: BRAFV600E is the most frequent oncogene in differentiated thyroid cancer (DTC) occurring in about 50% of cases. Clinical trials with tyrosine kinase inhibitors (TKI) with specific activity against BRAF in metastatic radioiodine-resistant DTC (MRR-DTC) are ongoing. Very recently it has been demonstrated that DTC often consists of a mixture of tumor cells with wild-type and mutant BRAF. The subclonal occurrence of BRAFV600E in MRR-DTC could disable the therapy with BRAF targeted TKI and be responsible of the frequent defeats of this treatment. A therapeutic strategy based upon BRAF inhibitors in tumors bearing subclonal BRAFV600E could be initially successful hitting the tumor cells expressing the oncogene, and after the initial tumor growth arrest and/or shrinkage, the oncogene negative cells insensitive or less sensitive to the treatment, could restart the growth of the tumor causing the progression of the disease and the escape from the clinical response.
- Aims: To determine the impact of subclonal BRAFV600E on the efficacy of BRAF inhibitors in the treatment of MRR-DTC.
- Study design: Primary tumor tissues will be analyzed for the presence of BRAFV600E by pyrosequencing or other quantitative assay. If available, synchronous metastases and post-therapy metachronous metastases will be analyzed as well. The clinical response will be determined according to RECIST, and the association with the percentage of BRAFV600E alleles will be evaluated. Attention will be paid to the possible difference of BRAFwild-type/BRAFV600E ratio between primary tumors and synchronous metastases, primary tumors and post-therapy metachronous metastases, and between responsive and resistant synchronous tumor lesions.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •subjects any sex any age with metastatic or unresectable thyroid carcinoma treated with tyrosine kinase inhibitors
- •evidence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)
- •availability of study end points including best response, duration of response, and time to disease progression (based on RECIST), clinical progression, or death
- •availability of tumor tissue samples, frozen or formaldehyde fixed-paraffin embedded from block, genomic DNA already extracted from tumor tissue
排除标准
- •concurrent Hashimoto's thyroiditis
结局指标
主要结局
Percentage of BRAFV600E alleles in tumor tissue before TKI treatment
时间窗: within 1 month after the patient has entered the study
次要结局
- Percentage of BRAFV600E alleles in tumor tissue post-TKI treatment(within 30 days from the availability of the tissue sample)
研究者
Mario Vitale
Professor of Endocrinology at the School of Medicine, University of Salerno, Director of the Endocrinology Unit, University Hospital of Salerno, Italy
University of Salerno
研究点 (1)
Loading locations...
相似试验
已完成
不适用
BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid CancerThyroid CancerNCT03363347Heidelberg University25
Unknown
不适用
Percentage of BRAFV600E Alleles and Outcome in Thyroid CarcinomaPapillary Thyroid CancerNCT04664413University of Salerno300
尚未招募
Unknown
BRAFV600E immunoprofiling in precancerous and cancerous lesions of the breast by immunohistochemistry and to study its association with clinicopathological features.CTRI/2023/06/053430Indian council of medical research
已完成
不适用
Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436Papillary Thyroid CarcinomaNCT01534897Massachusetts General Hospital10
Unknown
早期 1 期
BRAF V600E Mutations In Papillary Thyroid CarcinomaPapillary Thyroid CarcinomaNCT01417442Bezmialem Vakif University150